Residency · Residency · Nephrology

Acute Kidney Injury - Classification and Management

Introduction

Acute kidney injury is a clinical syndrome of heterogeneous etiology characterized by an abrupt decline in kidney function, affecting 10 to 15 percent of all hospitalized patients and up to 50 percent of patients admitted to the intensive care unit. AKI is associated with substantial short-term mortality, reaching 20 to 60 percent in the ICU setting, and carries long-term consequences including prolonged hospitalization, increased risk of chronic kidney disease, and progression to end-stage renal disease. AKI is not a single disease but rather a syndrome encompassing a wide range of pathophysiologic processes, and its management requires systematic evaluation to identify and address the underlying cause.

Definition and Staging

KDIGO Criteria (2012)

The Kidney Disease: Improving Global Outcomes (KDIGO) consensus criteria, published in 2012, standardized the definition of AKI and unified the previously competing RIFLE and AKIN classification systems. AKI is defined by any of the following: a rise in serum creatinine of 0.3 mg/dL or more within 48 hours, a rise in serum creatinine to 1.5 times or more above the baseline value within 7 days, or a urine output less than 0.5 mL/kg/hr sustained for 6 hours.

KDIGO Staging

Limitations of Creatinine-Based Definitions

Serum creatinine, while the most widely used marker of kidney function, has significant limitations as a diagnostic tool in AKI. The rise in serum creatinine lags behind the actual decline in glomerular filtration rate by 24 to 48 hours, meaning that significant kidney injury may be present before creatinine begins to rise. Aggressive fluid resuscitation, common in critically ill patients, dilutes serum creatinine and may underestimate the severity of AKI. Creatinine production depends on muscle mass, and patients with sarcopenia, liver disease, or critical illness may have lower baseline creatinine production, further obscuring the diagnosis. The emerging concept of subclinical AKI recognizes that tubular injury biomarkers may be positive while creatinine remains within normal limits, identifying a population with kidney damage that would be missed by traditional creatinine-based criteria alone.

Classification by Etiology

Pre-Renal AKI (~55-60% of cases)

Pre-renal AKI is the most common category, accounting for approximately 55 to 60 percent of cases, and results from decreased effective renal perfusion with preserved tubular function. The causes encompass any condition that reduces renal blood flow, including hypovolemia from hemorrhage, dehydration, or gastrointestinal losses; cardiorenal syndrome with low cardiac output; hepatorenal syndrome; the early vasodilatory phase of sepsis; and bilateral renal artery stenosis unmasked by ACE inhibitor or angiotensin receptor blocker therapy. The hallmark laboratory findings reflect intact tubular function with enhanced sodium and water reabsorption: fractional excretion of sodium (FENa) below 1 percent, fractional excretion of urea (FEUrea) below 35 percent, urine osmolality exceeding 500 mOsm/kg, and a bland urine sediment without cellular elements. The BUN-to-creatinine ratio typically exceeds 20:1, reflecting enhanced proximal urea reabsorption driven by the slow tubular flow rates. Pre-renal AKI is by definition reversible with restoration of renal perfusion through volume repletion or improvement in cardiac output, provided that treatment occurs before prolonged hypoperfusion leads to ischemic tubular necrosis.

Intrinsic Renal AKI (~35-40%)

Acute Tubular Necrosis (ATN)

Acute tubular necrosis is the most common cause of intrinsic renal AKI and represents the extension of pre-renal injury or direct tubular toxicity. Ischemic ATN results from prolonged pre-renal states, post-surgical hypoperfusion, sepsis, or any form of sustained circulatory shock. Nephrotoxic ATN may be caused by aminoglycosides, cisplatin, iodinated contrast media, myoglobin released during rhabdomyolysis, free hemoglobin from hemolysis, ethylene glycol, or the massive uric acid and phosphate burden of tumor lysis syndrome. The urine sediment in ATN is characterized by muddy brown granular casts and renal tubular epithelial cells, findings that are highly specific for tubular injury. The FENa typically exceeds 2 percent and the FEUrea exceeds 50 percent, reflecting impaired tubular sodium reabsorption. ATN progresses through four phases: initiation, during which the insult occurs and GFR begins to fall; extension, during which ongoing inflammation and microvascular injury propagate the damage; maintenance, the oliguric phase lasting one to three weeks during which GFR is markedly reduced; and recovery, the polyuric phase during which tubular function is restored but a concentrating defect persists.

Acute Interstitial Nephritis (AIN)

Acute interstitial nephritis accounts for 15 to 27 percent of AKI cases on renal biopsy and is most commonly drug-induced, with offending agents including penicillins, cephalosporins, NSAIDs, proton pump inhibitors, allopurinol, sulfonamides, and immune checkpoint inhibitors. The classic triad of fever, rash, and eosinophilia, traditionally associated with AIN, is present in fewer than 10 percent of cases, making clinical diagnosis unreliable. Urinalysis may reveal white blood cell casts, sterile pyuria, and eosinophiluria, though the sensitivity and specificity of these findings are poor. Definitive diagnosis requires renal biopsy, which demonstrates interstitial edema, an inflammatory infiltrate composed of lymphocytes and eosinophils, and tubulitis with inflammatory cells invading the tubular epithelium.

Acute Glomerulonephritis

Acute glomerulonephritis presents with the nephritic syndrome, characterized by hematuria with dysmorphic red blood cells and red blood cell casts, proteinuria, hypertension, and oliguria. Rapidly progressive glomerulonephritis, defined histologically by the presence of crescents in more than 50 percent of glomeruli, requires urgent evaluation and treatment to prevent irreversible loss of renal function. The differential diagnosis includes anti-GBM disease, ANCA-associated vasculitis, lupus nephritis, IgA nephropathy, and post-infectious glomerulonephritis.

Vascular Causes

Vascular causes of intrinsic AKI include the thrombotic microangiopathies, which encompass hemolytic uremic syndrome, thrombotic thrombocytopenic purpura, malignant hypertension, scleroderma renal crisis, complement-mediated atypical HUS, and drug-induced TMA from calcineurin inhibitors or gemcitabine. Renal artery thrombosis or embolism, atheroembolic disease from cholesterol crystal embolization, and renal vein thrombosis are additional vascular causes. Atheroembolic AKI is a particularly important entity that typically occurs days to weeks after vascular catheterization or initiation of anticoagulation, and presents with livedo reticularis, blue toe syndrome, peripheral eosinophilia, low complement levels, and the pathognomonic finding of biconvex cleft-shaped cholesterol crystal spaces on renal biopsy.

Post-Renal AKI (~5-10%)

Post-renal AKI results from urinary tract obstruction and accounts for approximately 5 to 10 percent of AKI cases. Obstruction must be bilateral, or unilateral in a patient with a solitary functioning kidney, to cause AKI. Common causes include benign prostatic hyperplasia, malignancy involving the cervix, bladder, or prostate, retroperitoneal fibrosis, nephrolithiasis in bilateral ureters or a solitary kidney, and neurogenic bladder. The primary diagnostic tool is renal ultrasonography, which demonstrates hydronephrosis, though this finding may be absent in early obstruction, retroperitoneal fibrosis, or severe volume depletion. Post-obstructive diuresis, a phenomenon of massive polyuria that occurs after relief of bilateral obstruction, can cause life-threatening volume depletion and electrolyte derangements. Management involves replacing 50 to 75 percent of the urine output with 0.45 percent saline and close monitoring of serum electrolytes.

<image>Comprehensive diagnostic algorithm for acute kidney injury. Start with confirming AKI by KDIGO criteria. First step: rule out post-renal obstruction with renal ultrasound (hydronephrosis present → urology consult, catheter/stent placement). If no obstruction, assess volume status and hemodynamics to differentiate pre-renal from intrinsic AKI. Show a comparison table of urinary indices: FENa, FEUrea, urine osmolality, urine sodium, BUN:Cr ratio, and urine sediment findings for pre-renal AKI versus ATN versus AIN versus GN. Include a note about FENa limitations (unreliable with diuretics; use FEUrea instead). For intrinsic AKI, branch into ATN (muddy brown casts), AIN (WBC casts, eosinophiluria), GN (RBC casts, dysmorphic RBCs), and vascular (schistocytes, LDH elevation). Include renal biopsy indications.</image>

Novel Biomarkers

Damage Biomarkers

Neutrophil gelatinase-associated lipocalin (NGAL) is one of the most extensively studied tubular injury biomarkers, rising within 2 to 4 hours of tubular injury in both serum and urine, well before creatinine begins to increase. NGAL is FDA-approved and has demonstrated utility in early detection of AKI in post-surgical and critically ill populations. Kidney injury molecule-1 (KIM-1) is a type I transmembrane glycoprotein expressed on the apical surface of proximal tubular cells that is markedly upregulated in ischemic and nephrotoxic injury. Interleukin-18 is a pro-inflammatory cytokine that is elevated in ischemic ATN but not in pre-renal AKI or urinary tract infection, providing some diagnostic specificity. Liver-type fatty acid-binding protein (L-FABP) is another proximal tubule injury marker that has shown promise in early AKI detection.

Stress Biomarkers

The product of tissue inhibitor of metalloproteinases-2 (TIMP-2) and insulin-like growth factor-binding protein 7 (IGFBP-7), commercially available as NephroCheck, represents a fundamentally different approach to AKI biomarkers by measuring cell cycle arrest, a cellular stress response that precedes overt injury. A product exceeding 0.3 (ng/mL)2/1000 indicates moderate risk, while a product exceeding 2.0 indicates high risk for development of KDIGO stage 2 or 3 AKI within 12 hours. This biomarker panel was validated in the SAPPHIRE and OPAL studies and is FDA-approved for AKI risk prediction in post-surgical and ICU settings.

Functional Biomarkers

Cystatin C, a low-molecular-weight protein produced at a constant rate by all nucleated cells and freely filtered by the glomerulus, rises earlier than creatinine in AKI, typically at 12 to 24 hours compared to 24 to 48 hours for creatinine. Proenkephalin (penKid) is an emerging functional biomarker that correlates with GFR in real-time and may provide a more accurate assessment of current kidney function than creatinine.

Management

Volume Assessment and Resuscitation

Optimal fluid management in AKI requires avoiding both extremes: hypovolemia perpetuates ischemic injury, while fluid overload is independently associated with worse outcomes. The FACTT trial in patients with acute respiratory distress syndrome demonstrated that a conservative fluid strategy was associated with improved lung function and reduced need for dialysis compared to a liberal strategy. When volume resuscitation is indicated, balanced crystalloids are preferred over normal saline based on the SMART and SALT-ED trials, which showed reduced rates of major adverse kidney events with balanced crystalloids. Albumin has not demonstrated clear benefit over crystalloids for AKI prevention in the general population, as established by the SAFE trial, although it may have a role in specific settings such as hepatorenal syndrome and spontaneous bacterial peritonitis.

Hemodynamic Optimization

A target mean arterial pressure of at least 65 mmHg is recommended for most patients, though a higher target of approximately 80 mmHg may be appropriate in patients with chronic hypertension, as suggested by the SEPSISPAM trial subgroup analysis. Norepinephrine is the first-line vasopressor in septic shock. Vasopressin may serve as an adjunctive vasopressor and showed a trend toward reduced AKI incidence in the VANISH trial, though the result did not reach statistical significance. The concept of "renal dose dopamine" has been definitively abandoned, as the ANZICS trial and subsequent meta-analyses showed no benefit in preventing or treating AKI.

Medication Management

Dose adjustment of renally cleared medications is essential during AKI, with particular attention to vancomycin, aminoglycosides, and enoxaparin. ACE inhibitors and angiotensin receptor blockers should be held during acute illness and resumed once creatinine has stabilized. NSAIDs should be avoided. Metformin should be held due to the risk of lactic acidosis if kidney function continues to deteriorate. In suspected AIN, the potentially offending drug should be promptly discontinued.

Indications for Renal Replacement Therapy

The absolute indications for renal replacement therapy in AKI are captured by the mnemonic AEIOU. Acidosis refers to severe metabolic acidosis with pH below 7.1 that is refractory to medical management with sodium bicarbonate. Electrolytes refers to refractory hyperkalemia with serum potassium exceeding 6.5 mEq/L with electrocardiographic changes despite maximal medical therapy. Intoxication refers to poisoning with dialyzable toxins including methanol, ethylene glycol, salicylates, and lithium. Overload refers to volume overload refractory to diuretic therapy, manifesting as pulmonary edema. Uremia refers to uremic complications including encephalopathy, pericarditis, and uremic bleeding.

Timing of RRT Initiation

The optimal timing of RRT initiation in AKI without absolute indications has been addressed by several landmark randomized controlled trials. The STARRT-AKI trial in 2020 demonstrated no benefit of accelerated RRT initiation within 12 hours of stage 2-3 AKI compared to a standard strategy of watchful waiting, and notably, the accelerated strategy led to unnecessary RRT in 38 percent of patients who would have recovered kidney function without dialysis. The AKIKI trial in 2016 similarly showed no benefit of early versus delayed initiation in stage 3 AKI. The IDEAL-ICU trial in 2018 was stopped for futility, showing no difference between early and delayed strategies in septic shock with AKI. The current evidence supports an individualized approach: RRT should be initiated promptly for absolute indications, but watchful waiting is appropriate and safe for most patients with stage 3 AKI without these urgent indications.

<image>Visual summary of major RRT timing trials in AKI. Create a comparison graphic showing the STARRT-AKI (2020, n=2927), AKIKI (2016, n=620), AKIKI-2 (2021, n=278), and IDEAL-ICU (2018, n=488) trials side by side. For each trial, show the enrollment criteria, definition of early vs delayed/standard initiation, primary outcome, mortality results (with confidence intervals), and percentage of patients in the delayed group who never required RRT. Highlight the consistent finding across trials that early initiation provides no mortality benefit and exposes patients to unnecessary RRT. Include a bottom panel summarizing current KDIGO recommendations for RRT initiation.</image>

AKI to CKD Transition

AKI is now recognized as an independent risk factor for the development of chronic kidney disease, with the risk increasing proportionally with AKI severity and recurrence. The pathophysiology of the AKI-to-CKD transition involves maladaptive repair processes, including G2/M cell cycle arrest in tubular cells, activation of profibrotic signaling pathways mediated by TGF-beta and connective tissue growth factor, peritubular capillary rarefaction leading to chronic hypoxia, and persistent interstitial inflammation that promotes fibrosis. Current guidelines recommend nephrology referral within 90 days for all patients who experience KDIGO stage 2 or 3 AKI, with monitoring of serum creatinine, proteinuria, and blood pressure at three months following the episode. RAAS inhibitors should be resumed when appropriate, as observational data suggest an association between post-AKI RAAS inhibitor use and improved survival.

Key Clinical Pearls

• FENa is unreliable in patients on diuretics; use FEUrea (<35% pre-renal, >50% intrinsic) instead
• Urine microscopy is the "renal biopsy of the nephrology fellow": muddy brown casts = ATN, RBC casts = GN, WBC casts = AIN/pyelonephritis; master this skill
• Post-obstructive diuresis can cause life-threatening volume depletion and electrolyte derangements; monitor and replace judiciously but avoid perpetuating the diuresis with excessive fluid replacement
• The STARRT-AKI trial established that watchful waiting is safe for most AKI patients without absolute RRT indications; approximately 40% of patients with severe AKI will recover without ever needing RRT
• Every episode of AKI increases the lifetime risk of CKD progression; structured post-AKI follow-up is critical

References

1. Kellum JA, Romagnani P, Ashuntantang G, et al. Acute kidney injury. Nat Rev Dis Primers. 2021;7(1):52.
2. STARRT-AKI Investigators. Timing of Initiation of Renal-Replacement Therapy in Acute Kidney Injury. N Engl J Med. 2020;383(3):240-251.
3. Kashani K, Al-Khafaji A, Ardiles T, et al. Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury (SAPPHIRE). Crit Care. 2013;17(1):R25.
4. Chawla LS, Bellomo R, Bihorac A, et al. Acute kidney disease and renal recovery: consensus report of the Acute Disease Quality Initiative (ADQI) 16 Workgroup. Nat Rev Nephrol. 2017;13(4):241-257.
5. Semler MW, Self WH, Wanderer JP, et al. Balanced Crystalloids versus Saline in Critically Ill Adults. N Engl J Med. 2018;378(9):829-839.

Read this lecture as Markdown